MedTrace Logo

Neurofilament Assay for the Diagnosis of ALS

NCT05077696 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2021-10-14

No results posted yet for this study

Summary

The aim of the study is to evaluate the interest of the determination of pNFH and NFL neurofilaments in serum for the diagnosis of ALS in patients with a diagnostic standoff after evaluation in an expert ALS center. The hypothesis is that one of these biomarkers, or their combined analysis, will make it possible to confirm or invalidate the diagnosis of ALS.

Conditions

  • Progressive Motor Neuron Disease Without Definite Diagnosis

Interventions

OTHER

Drawing a tube of blood (serum)

dosage of neurofilaments and comparison with a final diagnosis one year after sampling.

Sponsors & Collaborators

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-01
Primary Completion
2023-11-01
Completion
2023-11-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05077696 on ClinicalTrials.gov